RVL Pharmaceuticals plc
RVLPDelisted Nov 20, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001739426
RVL Pharmaceuticals plc was delisted on Nov 20, 2023; its insiders filed their last Form 4 on Oct 23, 2023; 32 institutions reported holding it in 13F filings for Q3 2023, worth $1.57M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 32
- Q3 2023, −4 vs. previous quarter
- 13F value
- $1.57M
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding RVLP, Q3 2023
No superinvestor reported holding RVLP at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by RVL Pharmaceuticals plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 2023 (view filing)4:23 PM ET | Oct 19-20 | 4 days | Harsaul Foundation10% Owner | SSale | −14.1M | $0.0411 | −$580.1K | −74.1%4.94M after | 2 lotsDuplicate filing |
| Oct 23, 2023 (view filing)1:06 PM ET | Oct 19-20 | 4 days | Altchem Ltd and 1 other10% Owner | SSale | −14.1M | $0.0411 | −$580.1K | −74.1%4.94M after | 2 lots |
| Oct 20, 2023 (view filing)3:59 PM ET | Oct 18 | 2 days | Harsaul Foundation10% Owner | SSale | −3.42M | $0.0646 | −$221.0K | −15.2%19.1M after | Duplicate filing |
| Oct 20, 2023 (view filing)1:36 PM ET | Oct 18 | 2 days | Altchem Ltd and 1 other10% Owner | SSale | −3.42M | $0.0646 | −$221.0K | −15.2%19.1M after | |
| Aug 9, 2022 (view filing)5:18 PM ET | Aug 8 | 1 day | Avista Capital Partners III GP, L.P. and 3 others10% Owner | PPurchase | +8.00M | $1.55 | +$12.4M | +50.9%23.7M after | Duplicate filing |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Schaub JamesEVP and COO | PPurchase | +150.0K | $1.55 | +$232.5K | +38.5%540.0K after | |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Markison Brian AChief Executive Officer | PPurchase | +850.0K | $1.55 | +$1.32M | +40.0%2.98M after | |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Burgstahler David FDirector, 10% Owner | PPurchase | +8.00M | $1.55 | +$12.4M | +50.9%23.7M after | Duplicate filing |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Venkataraman SriramDirector, 10% Owner | PPurchase | +8.00M | $1.55 | +$12.4M | +50.9%23.7M after | |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Schaub JamesEVP and COO | PPurchase | +93.8K | $1.07 | +$100.4K | +30.1%405.9K after |
Top 10 13F holders, Q3 2023
The largest institutional positions in RVL Pharmaceuticals plc at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Athyrium Capital Management, LP | 14,600,444 | $1.26M | 1.11% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 1,079,515 | $93.0K | 0.00% | +384,600+55.3% | Added |
| Blackstone Group Inc. | 632,264 | $56.9K | 0.00% | +632,264 | New |
| Geode Capital Management, LLC | 307,266 | $26.6K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 272,584 | $23.6K | 0.00% | +249,043+1,057.9% | Added |
| Vanguard Group Inc | 246,353 | $21.3K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 225,727 | $19.5K | 0.00% | −6,114−2.6% | Reduced |
| State Street Corp | 106,487 | $9.22K | 0.00% | +27,800+35.3% | Added |
| Raymond James Financial Services Advisors, Inc. | 103,037 | $8.92K | 0.00% | +73,518+249.1% | Added |
| Titleist Asset Management, LLC | 100,142 | $8.67K | 0.00% | +12,500+14.3% | Added |